CYP2C19基因多态性对奥美拉唑药动学影响的系统评价

 目的 系统评价CYP2C19基因多态性对奥美拉唑药物代谢动力学的影响。方法 计算机检索截止至2012年2月的Cochrane、PubMed、Embase、CNKI等数据库,收集有关CYP2C19基因多态性对奥美拉唑药动学影响的研究。用RevMan5.1软件对符合纳入标准的研究进行Meta分析。结果 共纳入12篇回顾性研究。其中英文8篇,中文4篇。Meta分析结果表明,CYP2C19基因多态性显著影响ρ_max、AUC、t_1/2和CL/F。PM基因型组的ρ_max、AUC和t_1/2的值均大于HEM基因型组,且HEM基因型组均显著大于EM基因型组;基因型为EM人群的CL/F显著大于HEM基因型组,HEM人群的CL/F也显著大于HM基因型组。结论 CYP2C19基因多态性显著影响奥美拉唑的体内代谢,但其代谢还受多种其他因素影响,尚需高质量大样本量的前瞻性研究来证实。

Systematic Review of Influence of CYP2C19 Genetic Polymorphism on Pharmacokinetics of Omeprazole

Objective To evaluate the influence of CYP2C19 genetic polymorphism on omeprazole pharmacokinetics. METHODS Cochrane library,PubMed,Embase and CNKI databases were searched for trials investigating the influence of CYP2C19 genetic polymorphism on omeprazole pharmacokinetics reported before February 2012. Meta-analysis was performed by RevMan 5.1 software. RESULTS Twelve retrospective studies,eight in English and four in Chinese,were included. Meta-analysis showed that CYP2C19 polymorphism significantly influenced the ρ_max,AUC,t_1/2 and CL/F. The ρ_max,AUC,t_1/2 and CL/F in PM genotype group were higher than those in HEM group,and those in HEM group were significantly higher than in EM group. And the CL/F in EM group was significantly higher than that in HEM group followed by that in PM group. CONCLUSION CYP2C19 genetic polymorphism affects omeprazole exposure significantly,but there are still other influencing factors. Large prospective studies are needed.